Benzoic acid amide compound

US10385011B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10385011-B2
Application numberUS-201615561585-A
CountryUS
Kind codeB2
Filing dateMar 30, 2016
Priority dateMar 31, 2015
Publication dateAug 20, 2019
Grant dateAug 20, 2019

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Disclosed are a novel benzoic acid amide derivative compound, an isomer thereof, a pharmaceutically acceptable salt thereof, a prodrug thereof, a hydrate thereof, or a solvate thereof. The novel compound and the like inhibit melanin production, prevent tyrosinase activity, and have an excellent skin whitening effect.

First claim

Opening claim text (preview).

The invention claimed is: 1. A compound of the following chemical formula 1, an isomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof: wherein R 1 of Chemical Formula 1 is selected from the group consisting of halogen, C 1 -C 5 alkyl, C 3 -C 6 cycloalkyl, C 3 -C 6 cycloalkenyl, and C 6 -C 18 aryl group, wherein the aryl group is unsubstituted or substituted with one or more selected from the group consisting of halogen, C 1 -C 5 alkyl, C 1 -C 5 alkoxy, methylenedioxy, and nitro groups. 2. The compound, the isomer thereof, the pharmaceutically acceptable salt thereof, the hydrate thereof, or the solvate thereof according to claim 1 , wherein the compound is selected from the group consisting of N-(2,4-dihydroxy-benzyl)-2,4-dimethoxy-5-methyl-benzoic acid amide, 5-bromo-N-(2,4-dihydroxy-benzyl)-2,4-dimethoxy-benzoic acid amide, 5-tert-butyl-N-(2,4-dihydroxy-benzyl)-2,4-dimethoxy-benzoic acid amide, N-(2,4-dihydroxy-benzyl)-2,4-dimethoxy-5-phenyl-benzoic acid amide, N-(2,4-dihydroxy-benzyl)-2,4-dimethoxy-5-(4-fluoro-phenyl)-benzoic acid amide, N-(2,4-dihydroxy-benzyl)-2,4-dimethoxy-5-(4-methoxy-phenyl)-benzoic acid amide, 5-benzo[1,3]dioxol-5-yl-N-(2,4-dihydroxy-benzyl)-2,4-dimethoxy-benzoic acid amide, 5-cyclohexene-1-yl-N-(2,4-dihydroxy-benzyl)-2,4-dimethoxy-benzoic acid amide, N-(2,4-dihydroxy-benzyl)-2,4-dimethoxy-5-(3,5-dimethyl-phenyl)-benzoic acid amide, 5-cyclohexyl-N-(2,4-dihydroxy-benzyl)-2,4-dimethoxy-benzoic acid amide, N-(2,4-dihydroxy-benzyl)-2,4-dimethoxy-5-(3,4-difluoro-phenyl)-benzoic acid amide, and N-(2,4-dihydroxy-benzyl)-2,4-dimethoxy-5-(3-nitro-phenyl)-benzoic acid amide. 3. The compound, the isomer thereof, the pharmaceutically acceptable salt thereof, the hydrate thereof, or the solvate thereof according to claim 1 , wherein the compound is N-(2,4-dihydroxy-benzyl)-2,4-dimethoxy-5-(3,5-dimethyl-phenyl)-benzoic acid amide. 4. A method of preparing the compound of chemical formula 1, the isomer thereof, the pharmaceutically acceptable salt thereof, the hydrate thereof, or the solvate thereof according to claim 1 , wherein the method comprises a first step of reacting a benzoic acid derivative of the following chemical formula 2 and a hydroxyl group substituted alkyl-phenyl amine as reactants: wherein R 1 of chemical formula 1 is selected from the group consisting of halogen, C 1 -C 5 alkyl, C 3 -C 6 cycloalkyl, C 3 -C 6 cycloalkenyl and C 6 -C 18 aryl group, wherein the aryl group is unsubstituted or substituted with one or more selected from the group consisting of halogen, C 1 -C 5 alkyl, C 1 -C 5 alkoxy, methylenedioxy, and nitro groups; and wherein R of chemical formula 2 is selected from the group consisting of halogen, C 1 -C 5 alkyl, C 3 -C 6 cycloalkyl, and C 3 -C 6 cycloalkenyl; wherein the first step is performed in presence of N-hydroxysuccinimide and N,N′-dicyclohexylcarbodiimide (DCC). 5. The method of preparing the compound of chemical formula 1 according to claim 4 , wherein the R of chemical formula 2 is halogen. 6. The method of preparing the compound of chemical formula 1 according to claim 5 , wherein the method further comprises a second step of reacting the resulting bromo benzoic acid amide derivative and arylboronic acid, in a case where the R of chemical formula 2 is bromine group to form a bromo benzoic acid derivative. 7. The method of preparing the compound of chemical formula 1 according to claim 6 , wherein the second step is performed in presence of a palladium catalyst under base condition. 8. The method of preparing the compound of chemical formula 1 according to claim 6 , wherein the aryl bromic acid is unsubstituted or substituted with one or more selected from the group consisting of halogen, C 1 -C 5 alkyl, C 1 -C 5 alkoxy, methylenedioxy, and nitro groups. 9. A method for skin whitening comprising administering the compound according to claim 1 , the isomer thereof, the pharmaceutically acceptable salt thereof, the hydrate thereof, or the solvate thereof to a subject in need thereof. 10. The method for skin whitening according to claim 9 , wherein the compound, the isomer thereof, the pharmaceutically acceptable salt thereof, the hydrate thereof, or the solvate thereof is contained in a composition in a concentration of 0.01 wt % to 20 wt % based on total weight of the composition. 11. The method for skin whitening according to claim 9 , wherein the compound, the isomer thereof, the pharmaceutically acceptable salt thereof, the hydrate thereof, or the solvate thereof inhibits melanin production. 12. The method for skin whitening according to claim 9 , wherein the compound, the isomer thereof, the pharmaceutically acceptable salt thereof, the hydrate thereof, or the solvate thereof inhibits tyrosinase activity. 13. The method according to claim 9 , wherein the compound, the isomer thereof, the pharmaceutically acceptable salt thereof, the hydrate thereof, or the solvate thereof is one for external application to skin. 14. The method according to claim 9 , wherein the compound, the isomer thereof, the pharmaceutically acceptable salt thereof, the hydrate thereof, or the solvate thereof is one for a cosmetic composition, a pharmaceutical composition, or health food composition.

Assignees

Inventors

Classifications

  • Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

  • Drugs for dermatological disorders · CPC title

  • for chemically bleaching or whitening the skin · CPC title

  • Amides · CPC title

  • having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10385011B2 cover?
Disclosed are a novel benzoic acid amide derivative compound, an isomer thereof, a pharmaceutically acceptable salt thereof, a prodrug thereof, a hydrate thereof, or a solvate thereof. The novel compound and the like inhibit melanin production, prevent tyrosinase activity, and have an excellent skin whitening effect.
Who is the assignee on this patent?
Amorepacific Corp
What technology area does this patent fall under?
Primary CPC classification A23L29/00. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Aug 20 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).